The Reality Check MedTech Executives Are Delivering About AI Implementation
Industry leaders at AdvaMed's conference warn that managing hundreds of AI agents in regulated environments poses far greater challenges than the technology hype suggests.
The artificial intelligence revolution in medical technology may be more evolutionary than many realize. At AdvaMed's The MedTech Conference, industry executives delivered a sobering assessment of AI deployment, revealing a significant gap between the technology's promise and its practical implementation in highly regulated healthcare environments.
While AI dominates industry conversations and conference agendas, the reality on the ground tells a different story. Ketryx CEO Erez Kaminski estimates that medtech companies have "hundreds of use cases, probably over 1,000" for AI applications, with approximately half concentrated in research and development. Yet despite this abundance of potential applications, Kaminski notes that AI is "much less deployed than people tend to believe."
The Hidden Complexity of AI at Scale
The challenge extends far beyond developing accurate algorithms. Industry leaders emphasized that managing hundreds of AI agents across regulated quality processes represents a complexity that exceeds current IT system management capabilities. This operational reality requires entirely new frameworks that define both AI responsibility and authority before actions occur.
Zahra Timsah, CEO of i-GENTIC AI, highlighted a particularly concerning dimension of this challenge: AI systems can produce technically accurate answers while simultaneously violating patient privacy, bypassing required approvals, or acting on outdated regulatory requirements. This disconnect between accuracy and compliance underscores why deployment lags behind development in the medtech sector.
Data-Driven Applications Show Promise
Some companies are making tangible progress with targeted AI implementations. ResMed CEO Mick Farrell reported that his company leverages 28 billion nights of sleep health data, serving 35 million patients through its AirView platform and more than 12 million users on myAir. ResMed is applying AI across supply chain operations to offset inflation costs, demonstrating practical value in specific operational domains.
Alexander Group Partner Mike White predicts that significant variation between productive and unproductive AI applications will emerge over the next 6-24 months, suggesting the industry is entering a critical sorting period where genuine value will separate from hype.
Strategic Implications for the Industry
The executive discussions revealed a consensus around strategic AI deployment: companies must balance vertical-specific AI expertise—where competitive advantage exists—with off-the-shelf solutions for general business functions. This approach acknowledges that not all AI applications deliver equal value, and that the complexity of managing numerous AI agents can detract from clinical and operational outcomes if not carefully implemented.
The medtech industry's measured approach to AI deployment reflects the high stakes of regulated healthcare environments, where patient safety and regulatory compliance cannot be compromised for technological novelty. As these leaders suggest, the path forward requires clear governance frameworks, targeted applications, and realistic expectations about implementation timelines—a far cry from the breathless AI enthusiasm often dominating tech headlines.
Sources
Google Search
Follow Health AI Central on Google
Choose Health AI Central as a preferred source, and Google is more likely to show our reporting in Top Stories.
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.